FDA CDER director candidates
NCI's Daniel Longo, MD, is one name that has been mentioned as a candidate to succeed Carl Peck. Longo is the associate director of the Biological Response Modifiers Program at the National Cancer Institute. Should FDA Commissioner Kessler choose Longo for the job, the selection may be seen as an effort to improve the agency's turbulent relationship with NCI and the oncology community, which last worsened over FDA's crackdown on alleged off-label promotions by Bristol-Myers Squibb for its cancer drugs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth